Adempas generic
Adempas is an anti-hypertensive drug owned by Bayer Healthcare. The active ingredient of Adempas is riociguat. This drug was first authorized for marketing on 08 October, 2013, and it is available in tablet form to be taken orally.
When will Adempas generic be available?
The patents protecting Adempas will expire on 18 February, 2034. This could potentially make way for the release of Adempas generics after this date.
Adempas uses
Adempas is used for the treatment of adults with chronic thromboembolic pulmonary hypertension (CTEPH), and pulmonary hypertension (PAH). The primary function of riociguat, the active ingredient, is to improve exercise capacity and the WHO functional class of patients.
Adempas patent expiration
Adempas, owned by Bayer Healthcare, has three patents protecting it. The most significant of these patents will expire on 18 February, 2034. The possibility of releasing Adempas generic version is likely after this date. Below are the details of the patent: